Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Giulia Somenzi"'
Autor:
Giulia Somenzi, Giusy Sala, Stefano Rossetti, MingQiang Ren, Riccardo Ghidoni, Nicoletta Sacchi
Publikováno v:
PLoS ONE, Vol 2, Iss 9, p e836 (2007)
Retinoic acid (RA), the bioactive derivative of Vitamin A, by epigenetically controlling transcription through the RA-receptors (RARs), exerts a potent antiproliferative effect on human cells. However, a number of studies show that RA can also promot
Externí odkaz:
https://doaj.org/article/525bf1271e8c4ab993160e4f5d35ff9d
Autor:
Giulia Somenzi, Francesca Corlazzoli, Jin Yao, Yijun Sun, Nicoletta Sacchi, Mingqiang Ren, Vincenzo Gagliostro, Stefano Rossetti, Nicolo Visconti
Publikováno v:
Oncotarget
A hallmark of cancer cells is the ability to evade the growth inhibitory/pro-apoptotic action of physiological all-trans retinoic acid (RA) signal, the bioactive derivative of Vitamin A. However, as we and others reported, RA can also promote cancer
Autor:
Nicoletta Sacchi, Silvia Pozzi, Mingqiang Ren, Gaia Bistulfi, Stefano Rossetti, Giulia Somenzi
Publikováno v:
Molecular and Cellular Biology. 25:10591-10603
Resistance to the growth-inhibitory action of retinoic acid (RA), the bioactive derivative of vitamin A, is common in human tumors. One form of RA resistance has been associated with silencing and hypermethylation of the retinoic acid receptor beta2
Autor:
Clelia Olgiati, Sylvie Ménard, Lucia Viganò, Manuela Campiglio, Giulia Somenzi, Alberta Locatelli, Luca Gianni, Marzia Fumagalli, Nicola Normanno
Publikováno v:
Journal of Cellular Physiology. 198:259-268
High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘Iressa’) has clinical activity in a wide range of tumor types
Autor:
Sylvie Ménard, Clelia Olgiati, Manuela Campiglio, Nadia Zaffaroni, P. Valagussa, Andrea Balsari, Giulia Somenzi, Giovanni Luca Beretta
Publikováno v:
International Journal of Cancer. 105:568-573
The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m2) as neoadjuvant c
Autor:
Nicola Normanno, Sylvie Ménard, Manuela Campiglio, A. De Luca, Monica R. Maiello, Luca Gianni, Giulia Somenzi, David S. Salomon, Fortunato Ciardiello
Publikováno v:
Annals of Oncology. 13:65-72
Background Co-expression of the epidermal growth factor receptor (EGFR) and of ErbB-2 is found in a subset of primary human breast cancer. Materials and methods The antiproliferative effects of anti-EGFR and anti-ErbB-2 agents were evaluated using a
Autor:
Giulia Somenzi, Sylvie Ménard, Fabio Castiglioni, Michele Modugno, Cecilia Melani, Cristina Ghirelli, Elda Tagliabue, Laura Asnaghi
Publikováno v:
Journal of Biological Chemistry. 275:5388-5394
Nerve growth factor (NGF) is known to exert a mitogenic effect on human breast cancer cells through proto-TrkA activation. Reverse transcriptase-PCR analysis of proto-TrkA expression in human breast carcinoma specimens and cell lines revealed trkA tr
Autor:
Francesca Scarlatti, Giulia Somenzi, Nicoletta Sacchi, Paola Signorelli, Giusy Sala, Riccardo Ghidoni
Publikováno v:
The FASEB Journal. 17:2339-2341
Resveratrol (3,4',5-trans-trihydroxystilbene), a phytoalexin present in grapes and red wine, is emerging as a natural compound with potential anticancer properties. Here we show that resveratrol can induce growth inhibition and apoptosis in MDA-MB-23
Autor:
Manuela, Campiglio, Alberta, Locatelli, Clelia, Olgiati, Nicola, Normanno, Giulia, Somenzi, Lucia, Viganò, Marzia, Fumagalli, Sylvie, Ménard, Luca, Gianni
Publikováno v:
Journal of cellular physiology. 198(2)
High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, al
Autor:
Manuela, Campiglio, Giulia, Somenzi, Clelia, Olgiati, Giovanni, Beretta, Andrea, Balsari, Nadia, Zaffaroni, Pinuccia, Valagussa, Sylvie, Ménard
Publikováno v:
International journal of cancer. 105(4)
The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m(2)) as neoadjuvant